Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | RXRB | P28702 | 2/20 | 0.45 |
| ▸ | RXRG | P48443 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.40 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636496 | 0.84 | RAB9A (0.50) | MRGPRX4RAB9ASMN1; SMN2KDM1APTGER1 | |
| SCHEMBL31166845 | 0.83 | RAB9A (0.49) | MRGPRX4RAB9ASMN1; SMN2KDM1APTGER1 | |
| SCHEMBL20756090 | 0.81 | RXRA (0.54) | MRGPRX4RXRARXRBRXRGHTR2C | |
| SCHEMBL20922980 | 0.79 | RAB9A (0.46) | MRGPRX4RAB9ASMN1; SMN2KDM1AHTR2C | |
| SCHEMBL29937257 | 0.78 | MRGPRX4 (0.49) | MRGPRX4RXRARXRBRXRGKDM1A | |
| SCHEMBL18893896 | 0.78 | MRGPRX4 (0.49) | MRGPRX4RXRARXRBRXRGKDM1A | |
| SCHEMBL26607385 | 0.78 | MAPT (0.45) | MRGPRX4RXRARXRBRXRGRAB9A | |
| SCHEMBL31611455 | 0.78 | RAB9A (0.48) | MRGPRX4RAB9ASMN1; SMN2KDM1APTGER1 | |
| SCHEMBL25337365 | 0.77 | KDM1A (0.49) | MRGPRX4RXRARXRBRXRGKDM1A | |
| SCHEMBL26133457 | 0.77 | MRGPRX4 (0.48) | MRGPRX4RXRARXRBRXRGKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| EP-3651752-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111065383-A | Carboxamides useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603351-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | MRGPRX4 635/4885RXRA 2370/4885RXRB 2814/4885 |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | MRGPRX4 635/4885RXRA 2370/4885RXRB 2814/4885 |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | MRGPRX4 635/4885RXRA 2370/4885RXRB 2814/4885 |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | MRGPRX4 635/4885RXRA 2370/4885RXRB 2814/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | MRGPRX4 635/4885RXRA 2370/4885RXRB 2814/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | MRGPRX4 635/4885RXRA 2370/4885RXRB 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.